CA2762555C - Dual targeting antibody of novel form, and use thereof - Google Patents

Dual targeting antibody of novel form, and use thereof Download PDF

Info

Publication number
CA2762555C
CA2762555C CA2762555A CA2762555A CA2762555C CA 2762555 C CA2762555 C CA 2762555C CA 2762555 A CA2762555 A CA 2762555A CA 2762555 A CA2762555 A CA 2762555A CA 2762555 C CA2762555 C CA 2762555C
Authority
CA
Canada
Prior art keywords
antibody
cancer
dual targeting
targeting antibody
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2762555A
Other languages
English (en)
French (fr)
Other versions
CA2762555A1 (en
Inventor
Jin San Yoo
Weon Sup Lee
Sung Woo Kim
Sang Ryeol Shim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmabcine Inc
Original Assignee
Pharmabcine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmabcine Inc filed Critical Pharmabcine Inc
Publication of CA2762555A1 publication Critical patent/CA2762555A1/en
Application granted granted Critical
Publication of CA2762555C publication Critical patent/CA2762555C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
CA2762555A 2009-05-20 2009-07-22 Dual targeting antibody of novel form, and use thereof Active CA2762555C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0044032 2009-05-20
KR1020090044032A KR101224468B1 (ko) 2009-05-20 2009-05-20 신규한 형태의 이중표적항체 및 그 용도
PCT/KR2009/004084 WO2010134666A1 (ko) 2009-05-20 2009-07-22 신규한 형태의 이중표적항체 및 그 용도

Publications (2)

Publication Number Publication Date
CA2762555A1 CA2762555A1 (en) 2010-11-25
CA2762555C true CA2762555C (en) 2018-02-20

Family

ID=43126324

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2762555A Active CA2762555C (en) 2009-05-20 2009-07-22 Dual targeting antibody of novel form, and use thereof

Country Status (13)

Country Link
US (1) US10125194B2 (enExample)
EP (1) EP2433968B1 (enExample)
JP (2) JP5744012B2 (enExample)
KR (1) KR101224468B1 (enExample)
CN (1) CN102428104B (enExample)
AU (1) AU2009346447B2 (enExample)
BR (1) BRPI0924535B1 (enExample)
CA (1) CA2762555C (enExample)
DK (1) DK2433968T3 (enExample)
ES (1) ES2605604T3 (enExample)
RU (1) RU2520824C2 (enExample)
SG (1) SG175971A1 (enExample)
WO (1) WO2010134666A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
LT2782598T (lt) 2011-11-23 2020-07-27 In3Bio Ltd. Rekombinantiniai baltymai ir jų terapinis panaudojimas
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
JP6144771B2 (ja) * 2012-11-21 2017-06-07 ファームアブシン インコーポレイテッド Ｖｅｇｆｒ−２とｄｌｌ４を標的とする二重標的抗体及びこれを含む薬学的組成物
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
KR102049991B1 (ko) 2013-03-28 2019-12-02 삼성전자주식회사 항 c-Met/항 Her2 이중 특이 항체
KR102074421B1 (ko) 2013-03-29 2020-02-10 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
HUE038741T2 (hu) * 2013-05-06 2018-11-28 Sanofi Sa Folyamatos többlépéses eljárás antitestek tisztítására
KR20150063728A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
AR100271A1 (es) 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2
CN106659782B (zh) 2014-05-23 2021-11-09 塞尔德克斯医疗公司 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
KR20160024639A (ko) 2014-08-26 2016-03-07 삼성전자주식회사 c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
WO2016060297A1 (ko) * 2014-10-16 2016-04-21 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
IL256562B2 (en) 2015-07-15 2024-07-01 Genmab As Human CD3 antibodies or chimeras
UA128304C2 (uk) 2016-07-14 2024-06-05 Ґенмаб А/С Мультиспецифічне антитіло до cd40 і cd137
KR102201992B1 (ko) * 2016-09-08 2021-01-12 주식회사 우리기술 clec14a에 특이적으로 결합하는 탈당화 항체 및 그 용도
CN116836285A (zh) 2017-03-09 2023-10-03 健玛保 针对pd-l1的抗体
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
JP7290013B2 (ja) 2017-08-04 2023-06-13 ジェンマブ エー／エス Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
JP2021516702A (ja) * 2018-03-19 2021-07-08 ファームアブシン・インコーポレイテッドＰｈａｒｍａｂｃｉｎｅ Ｉｎｃ． 抗−ｖｅｇｆｒ−２抗体
EP3768313A4 (en) * 2018-03-20 2022-01-05 Yuh, Chiou Hwa DUAL-FUNCTIONAL ANTIBODIES AGAINST VEGFR2 AND VEGFR3 DISHES
CN119881293A (zh) 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
BR112021005184A8 (pt) 2018-09-19 2022-08-16 Lava Therapeutics B V Imunoglobulina cd1d de dupla ação
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
CN120983617A (zh) 2018-11-06 2025-11-21 健玛保 抗体配制剂
SG11202108141VA (en) 2019-02-01 2021-08-30 Lava Therapeutics B V Novel cd40-binding antibodies
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
CA3136975C (en) * 2019-08-14 2024-06-25 Pharmabcine Inc. Anti-tie2 antibody and use thereof
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
AU2021236906A1 (en) 2020-03-18 2022-08-18 Genmab A/S Antibodies binding to B7H4
US20230227570A1 (en) 2020-05-08 2023-07-20 Genmab A/S Bispecific antibodies against cd3 and cd20
MX2023000448A (es) 2020-07-08 2023-04-20 Lava Therapeutics N V Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta.
AU2021322046A1 (en) 2020-08-06 2023-02-02 BioNTech SE Binding agents for coronavirus S protein
JP2023541860A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
CA3190349A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
JP2023545520A (ja) 2020-10-14 2023-10-30 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患を治療するための組成物及び方法
MX2023006832A (es) 2020-12-10 2023-08-22 Lava Therapeutics N V Anticuerpos que se unen a receptores de linfocitos t gamma-delta.
EP4298125A1 (en) 2021-02-26 2024-01-03 LAVA Therapeutics N.V. Antibodies that bind cd123 and gamma-delta t cell receptors
JP2024519212A (ja) 2021-05-07 2024-05-09 ジェンマブ エー／エス Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物
US20240262924A1 (en) 2021-06-21 2024-08-08 Genmab A/S Combination dosage regime of cd137 and pd-l1 binding agents
WO2023019171A1 (en) 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
AU2022344595A1 (en) 2021-09-13 2024-05-02 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
JP7503215B2 (ja) 2021-10-08 2024-06-19 ジェンマブ エー／エス Ｃｄ３０及びｃｄ３に結合する抗体
JP2024538958A (ja) 2021-10-21 2024-10-28 ラヴァ・セラピューティクス・エヌ・ヴイ ガンマデルタｔ細胞活性化抗体の使用
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
TW202509077A (zh) 2023-06-30 2025-03-01 丹麥商珍美寶股份有限公司 與纖維母細胞活化蛋白α及死亡受體４結合之抗體
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
TW202519261A (zh) 2023-07-27 2025-05-16 荷蘭商拉法醫療公司 用於治療癌症之結合γ-δ T細胞受體之抗體
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP0642585B1 (en) 1992-05-18 2005-12-28 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US7090843B1 (en) * 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
CA2482607C (en) * 2002-04-22 2013-06-11 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
EP1601697B1 (en) 2003-02-28 2007-05-30 Lonza Biologics plc Antibody purification by Protein A and ion exchange chromatography
US20090111146A1 (en) 2003-09-02 2009-04-30 National Institute Of Advanced Industrial Science Antibody Drug
CN100503640C (zh) * 2004-07-08 2009-06-24 中国人民解放军军事医学科学院生物工程研究所 一种抗肿瘤融合蛋白及其编码基因与应用
WO2006005361A1 (en) 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CN1884300A (zh) * 2005-06-24 2006-12-27 中国人民解放军军事医学科学院微生物流行病研究所 一种具有靶向功能的抗肝癌超抗原,其制备方法及用途
WO2008090958A1 (ja) * 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물

Also Published As

Publication number Publication date
JP5744012B2 (ja) 2015-07-01
EP2433968A4 (en) 2012-12-05
RU2520824C2 (ru) 2014-06-27
DK2433968T3 (en) 2016-12-19
ES2605604T3 (es) 2017-03-15
KR101224468B1 (ko) 2013-01-23
WO2010134666A1 (ko) 2010-11-25
EP2433968A1 (en) 2012-03-28
AU2009346447B2 (en) 2013-11-14
BRPI0924535A2 (pt) 2015-06-30
EP2433968B1 (en) 2016-09-07
CN102428104A (zh) 2012-04-25
US20120065380A1 (en) 2012-03-15
RU2011146088A (ru) 2013-06-27
JP2015119705A (ja) 2015-07-02
AU2009346447A1 (en) 2011-12-01
BRPI0924535B1 (pt) 2021-07-20
JP2012527234A (ja) 2012-11-08
US10125194B2 (en) 2018-11-13
KR20100125033A (ko) 2010-11-30
CN102428104B (zh) 2015-03-04
CA2762555A1 (en) 2010-11-25
SG175971A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
CA2762555C (en) Dual targeting antibody of novel form, and use thereof
KR102749378B1 (ko) Dll3 및 cd3에 결합하는 이중특이적인 항체 작제물
KR20120130658A (ko) 펩타이드가 융합된 이중표적항체 및 그 용도
US20220259547A1 (en) Automated biomass-based perfusion control in the manufacturing of biologics
IL303344A (en) Tetravalent FZD and WNT receptor binding antibody compounds
JP2024504124A (ja) 新規の抗グレムリン１抗体
US10280218B2 (en) Antibodies binding to BMP4, and uses thereof
US20210395298A1 (en) Downstream processing of bispecific antibody constructs
US20220396599A1 (en) Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
WO2025140619A1 (zh) 包含ccr8抗原结合结构域的多特异性抗体

Legal Events

Date Code Title Description
EEER Examination request